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Summary
 
Triggering of a T cell requires interaction between its specific receptor (TCR) and a peptide
antigen presented by a self–major histocompatibility complex (MHC) molecule. TCR recog-
nition of self-MHC by itself falls below the threshold of detection in most systems due to low
affinity. To study this interaction, we have used a read-out system in which antigen-specific
effector T cells are confronted with targets expressing high levels of MHC compared with the
 
selecting and priming environment. More specifically, the system is based on CD8
 
1
 
 T cells
 
selected in an environment with subnormal levels of MHC class I in the absence of 
 
b
 
2
 
-micro-
globulin. We observe that the MHC restriction element can trigger viral peptide-specific T
cells independently of the peptide ligand, provided there is an increase in self-MHC density.
Peptide-independent triggering required at least four times the natural in vivo level of MHC
expression. Furthermore, recognition of the restriction element at expression levels below this
threshold was still enough to compensate for lack of affinity to peptides carrying alanine substi-
tutions in major TCR contact residues. Thus, the specificity in TCR recognition and T cell
activation is fine tuned by the avidity for self-MHC, and TCR avidities for peptide and MHC
may substitute for each other. These results demonstrate a functional role for TCR avidity for
self-MHC in tuning of T cell specificity, and support a role for cross-reactivity on “self” during
T cell selection and activation.
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T
 
riggering of a CD8
 
1
 
 T cell requires TCR interaction
with a specific peptide bound to an MHC class I mol-
ecule. The requirement for the selecting MHC molecule in
recognition of antigen is known as MHC restriction (1, 2).
Although interactions between TCR and the restriction el-
ement have been detected only in the presence of specific
peptides, it is believed that thymic positive selection im-
poses a low self-MHC affinity onto the peripheral T cell
pool (3–6). Early studies of TCR–MHC interactions in-
volved analyses of MHC mutants for their ability to disrupt
T cell reactivity (7–9). Mutations in the 
 
a
 
-helical regions
in the 
 
a
 
1/
 
a
 
2 domains of the MHC molecule were found
to perturb recognition of specific antigen, indicating that
the TCR physically contacts the 
 
a
 
-helices of MHC mole-
cules. However, measurements of affinity between TCR
and peptide–MHC complexes have revealed relatively low
affinities for MHC in complex with agonist peptides and
slightly lower affinities for MHC in complex with antago-
nist peptides, whereas no detectable affinities have been
found for MHC in complex with unrelated peptides (10–
13). Thus, the idea of TCR affinity to self-MHC in the ab-
sence of specific antigen has been hard to support biochem-
ically.
Recently, crystallographic studies have shown a physical
interaction between TCR and MHC in the presence of
specific peptide (14, 15). Of the total surface area contacted
by the TCR in the MHC complex, approximately one
third is provided by the peptide while MHC 
 
a
 
1/
 
a
 
2 do-
mains contribute two thirds of the contact area. Based on
alanine scanning mutagenesis of the 2C TCR, it has been
estimated that almost two thirds of the binding energy in
antigen-specific binding is attributable to contacts with the
 
a
 
-helices (16). Does the interaction between TCR and
MHC as observed in crystallographic and biochemical
studies also contribute to the avidity required for T cell
triggering, and can it be detected in the absence of the spe-
cific peptide? Further, how does this interaction influence
T cell specificity for the antigenic peptide? The answers to 
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these questions are of major importance for the under-
standing of several aspects of physiological T cell function,
including MHC restriction (1, 2), thymic selection (17),
and maintenance of T cell memory (18). Interestingly, re-
cent evidence indicates that T cells require interaction with
endogenous peptide–MHC complexes for long-term sur-
vival, suggesting continuous cross-recognition of self for
maintenance of immunological memory (19–21).
T cell avidity for self has been demonstrated in func-
tional assays. CTLs triggered by allogeneic MHC can spe-
cifically kill bystander cells of self-MHC haplotype, indicat-
ing that self-MHC can mediate binding to CTLs that are
efficiently triggered by their antigen, although it cannot
trigger CTLs directly (22). Second, mice with low MHC
class I expression select T cells adapted to that environ-
ment, whose avidity to self-MHC is revealed when assessed
in the context of normal MHC class I levels. For example,
CTLs generated against allogeneic cells in such mice specif-
ically cross-react with cells expressing high levels of self-
MHC class I (23–25). Similarly, T cell hybridomas derived
from CD3
 
z
 
/
 
h
 
-deficient mice expressing very low levels of
cell surface TCR also react against cells expressing self-
MHC class I molecules, once a normal level of TCR ex-
pression has been restored by CD3
 
z
 
/
 
h 
 
transfection (26).
Thus, in systems where either the MHC or the TCR are
expressed at subnormal levels, it is possible to generate T
cells for the study of TCR affinity/avidity for self-MHC,
which are not present in normal mice with high MHC ex-
pression due to negative selection.
To study the role of self-MHC avidity in MHC-restricted
CTLs, we immunized 
 
b
 
2
 
-microglobulin–deficient (
 
b
 
2
 
m
 
2
 
/
 
2
 
)
 
1
 
mice, which have low expression of conformed MHC
class I (27, 28), with the H-2D
 
b
 
–restricted immunodomi-
nant lymphocytic choriomeningitis virus (LCMV) GP 33-
41 (GP33) peptide. We obtained CD8
 
1
 
 CTLs which were
specific for the GP33 epitope when loaded onto cells with
low MHC class I expression (MHC
 
low
 
). However, unlike
GP33-specific C57Bl/6 (B6) CTLs, these CTLs also killed
cells expressing high levels of self-MHC class I (MHC
 
high
 
)
in the absence of specific peptide. Further experiments re-
vealed a dual specificity of these CTLs: peptide specificity
against MHC
 
low
 
 targets, and peptide-independent specific-
ity for the restriction element when tested against MHC
 
high
 
targets. By mAb blocking of the MHC restriction element,
we found that peptide-independent triggering of a CTL
clone with high avidity for self-MHC required at least four
times the in vivo expression of MHC. Most interestingly,
at lower MHC expression an increased recognition of self-
MHC could compensate for lack of TCR interaction with
the specific peptide, as evaluated with peptides carrying ala-
nine substitutions in major TCR contact residues. These
results indicate that TCR avidity for the MHC molecule
functionally contributes to T cell specificity, and that TCR
 
affinities for MHC and peptide are interchangeable. Our
results have important implications for the understanding of
T cell specificity and the role of self-MHC in peripheral T
cell function.
 
Materials and Methods
 
Mice.
 
B6, transporter associated with antigen processing
(TAP)1
 
2
 
/
 
2
 
 (29), 
 
b
 
2
 
m
 
2
 
/
 
2 
 
(30, 31), and TAP1/
 
b
 
2
 
m
 
2
 
/
 
2
 
 (32) mice
of the H-2
 
b
 
 haplotype were bred at the Microbiology and Tumor
Biology Center, Karolinska Institute. Animal care was in accor-
dance with institutional guidelines. TAP1
 
2
 
/
 
2
 
, 
 
b
 
2
 
m
 
2
 
/
 
2
 
, and
TAP1/
 
b
 
2
 
m
 
2
 
/
 
2
 
 mice used were back-crossed to B6 background
6, 10, and 7 times, respectively. For thymectomy experiments,
 
b
 
2
 
m
 
2
 
/
 
2
 
 mice were 735 rad–irradiated and thymectomized or
sham-thymectomized, and reconstituted with 
 
b
 
2
 
m
 
2
 
/
 
2
 
 fetal liver
hematopoietic cells.
 
Cell Lines.
 
RMA is a subline of the Rauscher virus–induced
B6 lymphoma RBL-5, and RMA-S is a TAP2-deficient variant
of RMA (33). T2 is a hybrid between the two human cell lines
0.174 and CEM, and has an antigen-processing deficiency due to
a deletion on the MHC class II region including the TAP1 and
TAP2 genes. T2D
 
b
 
 is an H-2D
 
b
 
 transfectant of T2. All cell lines
were maintained at 37
 
8
 
C and 5% CO
 
2
 
 in RPMI 1640 tissue cul-
ture medium supplemented with 5% FCS, 50 
 
m
 
g/ml streptomy-
cin, 100 
 
m
 
g/ml penicillin, and 2 mM 
 
l
 
-glutamine. Con A–acti-
vated blasts were generated by culturing erythrocyte-depleted
splenocytes in 5 
 
m
 
g/ml of Con A for 2 d in tissue culture me-
dium as described above with 10% FCS.
 
Synthetic Peptides.
 
The following synthetic H-2D
 
b
 
–presented
peptides were synthesized using solid phase F-moc chemistry:
LCMV GP33 KAVYNFATM (34, 35); LCMV GP 33-4A
(GP33-4A) KAVANFATM; LCMV GP 33-34A (GP33-34A)
KAAANFATM; LCMV GP 33-348A (GP33-348A) KAAAN-
FAAM; influenza PR8 NP 366-374 (NP366) ASNENMETM
(36); and 
 
Yersinia enterocolitica
 
 Yop51 249-257 (Yop249) IQV-
GNTRTI (37).
 
Generation of LCMV GP33-specific CTL Cultures and Clones.
 
GP33-specific CD8
 
1
 
 CTLs were elicited in B6 and 
 
b
 
2
 
m
 
2
 
/
 
2
 
 mice
by peptide immunization (38). 100 
 
m
 
g peptide was dissolved in
distilled water and mixed with IFA in a 1:1 ratio by sonication,
then injected subcutaneously in the base of the tail. 12 d after im-
munization, 25 
 
3 
 
10
 
6
 
 immune spleen cells were cocultured with
25 
 
3 
 
10
 
6
 
 2,000 rad–irradiated B6 or 
 
b
 
2
 
m
 
2
 
/
 
2
 
 splenocytes in the
presence of 0.05 
 
m
 
M peptide in 12 ml complete medium (RPMI
1640 supplemented with 10% FCS, 0.1 mM nonessential amino
acids, 1 mM sodium pyruvate, 5 
 
3 
 
10
 
2
 
5
 
 M 2-ME, 2 mM 
 
l
 
-glu-
tamine, and 50 
 
m
 
g/ml streptomycin, 100 
 
m
 
g/ml penicillin) at
37
 
8
 
C and 5% CO
 
2
 
. 6–7 d later, these cells were used as effector
cells in a 
 
51
 
Cr-release assay. CTL clones were generated by limit-
ing dilution cloning. Long-term CTL clones and lines were
maintained in complete medium (see above) based on MEM-
 
a
 
and further supplemented with Hepes buffer and 20 IU/ml IL-2.
CTL clones and lines were restimulated in 12-d intervals with
2,000 rad–irradiated splenocytes in the presence of 0.05 
 
m
 
M pep-
tide.
 
mAbs and FACS
 
®
 
 Analysis.
 
B22-249.1 is a mouse mAb which
binds to a conformation-dependent epitope on the 
 
a
 
1 domain of
the H-2D
 
b
 
 molecule, and Y3 is a mAb which binds to con-
formed H-2K
 
b
 
 molecules. For flow cytometry with these mAbs,
cells were incubated with mAb for 30 min on ice, washed, and
then stained with goat anti–mouse Oregon Green conjugate
 
1
 
Abbreviations used in this paper:
 
 
 
b
 
2
 
m, 
 
b
 
2
 
-microglobulin; B6, C57Bl/6;
LCMV, lymphocytic choriomeningitis virus; TAP, transporter associated
with antigen processing. 
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(Molecular Probes) on ice for 30 min. For measurement of CD8
and TCR expression, CTLs were stained for 30 min with the
FITC-conjugated anti-CD8
 
a
 
 mAb 53-6.7 (PharMingen) and the
PE-conjugated anti–TCR-
 
a
 
/
 
b
 
 mAb H57-597 (PharMingen),
respectively. After washing, analysis was performed using a FAC-
Scan
 
®
 
 (Becton Dickinson) with CellQuest software.
 
CTL Assay, Cold Target Competition, and CTL Blocking with mAb.
 
CTL activity was measured in a standard 
 
51
 
Cr-release assay. In
brief, peptide-coated target cells were prepared by incubating
cells with indicated concentrations of peptide for 1 h at 37
 
8
 
C.
Coated cells were labeled with 10 
 
m
 
l 10 mCi/ml 
 
51
 
Cr for 1 h at
37
 
8
 
C. Titrated amounts of effector cells were incubated with 3 
 
3
 
10
 
3
 
 
 
51
 
Cr-labeled target cells for 4 h at 37
 
8
 
C, 5% CO
 
2
 
. After incu-
bation, released radioactivity was measured and specific lysis was
calculated according to the formula: % specific release 
 
5 
 
[(exper-
imental release 
 
2 
 
spontaneous release)/(maximum release 
 
2
 
spontaneous release)] 
 
3 
 
100. Cold temperature–treated target
cells were generated through culture of RMA-S at 26
 
8
 
C for 12 h
(39). For cold target competition experiments, effector T cells
and unlabeled (cold) competitor cells were mixed and preincu-
bated at 37
 
8
 
C for 30 min before addition of labeled (hot) target
cells. The assay was then run as a standard 51Cr-release assay for 4 h.
For blocking of CTL recognition with the B22-249.1 mAb, ti-
trated amounts of mAb were included in the CTL assay medium.
Results
Expression of Properly Conformed H-2Db in b2m2/2 Cells Is
TAP Dependent. We first compared the levels of properly
conformed H-2Db molecules on the cell surface of b2m2/2,
TAP1/b2m2/2, and B6 (TAP1/b2m1/1) control cells
stained with an mAb directed against H-2Db (B22-249.1)
or H-2Kb (Y3) conformation-sensitive epitopes. A substan-
tial level of conformed cell surface H-2Db molecules was
found on b2m2/2 cells, whereas conformed H-2Kb was de-
tected at lower levels, in line with previously published re-
sults (27, 28; Fig. 1). This is compatible with H-2Db being
more independent of b2m during folding and transport of
MHC class I free heavy chains (27, 28). On Con A blasts
deficient for both b2m and TAP1, the staining with B22-
249.1 was virtually at background levels, which implies that
the pool of conformed H-2Db molecules on b2m2/2 cells is
dependent on a functional TAP complex.
b2m2/2 Mice Have Thymus-dependent CD81 T Cells that
Mount an H-2Db–restricted and Peptide-specific CTL Response
against the LCMV GP33 Epitope. B6 and b2m2/2 mice
were immunized with antigenic peptides restricted to ei-
ther H-2Db or H-2Kb. All tested peptides primed responses
in B6 mice (data not shown), whereas only one, the H-2Db–
restricted LCMV GP33, primed a response in b2m2/2
mice. This is in line with the low but significant levels of
folded H-2Db molecules on the surface of b2m2/2 cells
(27; Fig. 1). CTLs from both B6 and b2m2/2 mice primed
with the GP33 peptide killed RMA-S cells pulsed with the
GP33 peptide used for priming but not a control influenza
NP366 peptide (Table I). CTL responses were mediated by
CD81 cells as determined by mAb- and complement-medi-
ated depletion of effector populations in vitro (data not
shown). FACS® analysis of both polyclonal bulk popula-
tions and clones confirmed the TCR1CD81 phenotype of
the responding CTLs in b2m2/2 as well as B6 mice (Fig. 2).
Cell surface expression levels of both TCR and CD8 were
similar in CTLs from b2m2/2 and B6 mice. However, a
marginal increase in CD8 expression levels was detected in
some b2m2/2 CTLs compared with B6 CTLs. This increase
may be due to the low levels of H-2Db expressed during se-
lection and priming in the absence of b2m. However, lysis
performed by b2m2/2 CTLs did not show increased depen-
dency on CD8 compared with B6 CTLs, as determined by
mAb blocking of CD8 (data not shown).
No priming of CTLs was observed in thymectomized
b2m2/2 mice that had been irradiated and reconstituted
with fetal liver (Table I). Control mice (receiving irradia-
tion and fetal liver reconstitution without thymectomy)
generated a normal antipeptide CTL response, showing
that the responding CD81 T cell population in b2m2/2
mice was dependent on the thymus for development. In
addition, a normal antipeptide response was also found in
mice that had been thymectomized but not irradiated,
showing that the thymus was not necessary during the
Figure 1. H-2Db expression in the absence of b2m is TAP dependent.
FACS® analysis of H-2Db and H-2Kb expression on Con A–activated
blasts from B6 (A), b2m2/2 (B), and TAP1/b2m2/2 (C) mice using the
B22-249.1 and Y3 mAbs, respectively. Bold and dotted lines represent
H-2Db and H-2Kb expression, respectively. Solid thin line represents
staining with secondary antibody only.886 Functional Recognition of MHC Modulates T Cell Specificity
priming of the response (Table I). The latter control indi-
cated that the generated CTLs were not positively selected
in the thymus in response to the peptide injected for
immunization. We conclude that b2m2/2 mice have a
peripheral pool of CD81 T cells which are thymus de-
pendent, H-2Db restricted, and peptide specific despite ex-
pressing very low levels of H-2Db molecules, correspond-
ing to a few percent of those expressed by B6 mice.
GP33-specific b2m2/2 CTLs Have an Increased Avidity for
H-2Db Molecules. Alloreactive CTLs from mice with low
MHC class I expression have an increased avidity to self-
MHC (23). By priming peptide-specific, self-MHC–
restricted CTLs in b2m2/2 mice it is possible to study the
role of self-MHC avidity for T cell specificity in MHC-
restricted T cells. To compare the avidity for self-MHC class
I in B6 and b2m2/2 CTLs specific for the GP33 peptide,
these CTLs were tested for their ability to kill RMA target
cells (MHChigh) in the absence of loaded peptides. B6 CTLs
failed to kill RMA cells, whereas b2m2/2 CTLs efficiently
killed these target cells (Fig. 3, A and B, respectively). Cold
target competition experiments made with bulk CTLs
showed that the b2m2/2 CTL killing of labeled RMA cells
was completely inhibited by RMA-S pulsed with GP33
but not by RMA-S without peptide (Fig. 3 C). This
showed that a majority of the clones in the b2m2/2 CTL
population were specific for both self-MHC expressed at
high levels and the peptide antigen presented by MHC at
low levels.
Three GP33-specific b2m2/2 CTL clones were gener-
ated, all of which also killed RMA cells. However, the
clone C10 was more efficient in killing RMA-S loaded
with GP33 compared with RMA (Fig. 3 D), whereas clone
27/30 killed RMA slightly better than RMA-S plus GP33
(Fig. 3 E), and clone 3C5 killed both of these target cells to
a similar extent (Fig. 3 F). This pattern is compatible with a
clonal variation in TCR avidity for peptide versus MHC
within the b2m2/2 CTL population. In line with the re-
sults obtained with bulk cultures, the GP33-specific B6
CTL clone 2C10 did not recognize RMA in the absence of
GP33 peptide (Fig. 3 G).
To test the reactivity of the CTLs against MHC class I in
the absence of peptides, we used RMA-S cells incubated at
Table I. Development of Peptide-specific b2m2/2 CTLs Is Thymus Dependent
Treatment Target E:T
Responder mouse strain
b2m2/2* B6 b2m2/2 b2m2/2 b2m2/2
Thymectomy‡ 22 2 1 1
Irradiation and reconstitution 22 1 1 2
RMA-S plus GP33 45:1 49 79 47 1 41
15:1 38 55 37 1 20
5:1 23 34 15 0 12
RMA-S plus NP366 45:1 3 1 222
15:1 2 0 222
5:1 2 0 222
RMA-S, no peptide 45:1 3 2 0 0 2
15:1 3 1 2 0 0
5:1 0 0 4 0 3
*Mice immunized with synthetic LCMV GP33 peptide were restimulated in vitro and tested in a 51Cr-release assay against RMA-S cells coated with
the indicated peptides as described in Materials and Methods.
‡b2m2/2 mice were thymectomized or sham-thymectomized, 735 rad–irradiated, and reconstituted with fetal liver hematopoietic cells as indicated.
Figure 2. TCR and CD8 coreceptor expression in b2m2/2 and B6
CTLs. FACS® analysis of TCR-a/b and CD8a in GP33-specific CTLs,
using the PE-conjugated anti–TCR-a/b mAb H57-597 and the FITC-
conjugated anti-CD8a mAb 53-6.7 (PharMingen), respectively. Solid
lines represent B6 CTLs; dotted lines represent b2m2/2 CTLs. In staining
of CTL clones, the representative clones 2C10 (B6) and 3C5 (b2m2/2)
were used. The histograms show CD8 expression and TCR expression in
TCR1 and CD81 cells, respectively.887 Sandberg et al.
cold temperature (268C), which induce high levels of func-
tionally “empty” MHC class I molecules (39), and T2Db
cells expressing Db molecules mostly devoid of peptides.
Clone 27/30 also killed RMA-S cells after cold tempera-
ture incubation (Fig. 4 A). Furthermore, T2Db was recog-
nized irrespective of loaded peptide, whereas T2 control
targets were not killed (Fig. 4 B). Thus, the b2m2/2 CTL
clone 27/30 displays an avidity for the restriction element
of the GP33 peptide, even in the absence of specific pep-
tide. It should be noted that these CTLs were primed to re-
spond only against GP33, indicating that the ability to rec-
ognize self-MHC had been selected for during thymic
development and priming. Although these results do not
exclude that b2m2/2 CTLs also have an increased avidity
for self-peptides, we use the term “peptide independent” to
describe the specificity for the restriction element displayed
by the GP33-specific b2m2/2 CTLs.
Triggering of GP33-specific b2m2/2 CTLs Uses a Higher
Number of MHC Ligands to Compensate for Absence of Specific
Peptide. We next compared the avidity of b2m2/2 CTLs
for self-MHC with and without added GP33, by blocking
of the H-2Db ligands. We used an mAb specific for prop-
Figure 3. Elevated self-MHC reactivity in b2m2/2 CTLs. CTLs generated by synthetic LCMV GP33 peptide immunization (as described in Materials
and Methods) in B6 (A) and b2m2/2 (B) mice were tested against RMA-S, RMA, and RMA-S loaded with GP33 in a 51Cr-release CTL assay. (C)
b2m2/2 GP33-specific CTL lysis of 51Cr-labeled (hot) RMA target cells was subjected to cold target competition using cold (unlabeled) RMA-S, RMA,
and RMA-S loaded with GP33. b2m2/2 CD81 CTL clones C10 (D), 27/30 (E), and 3C5 (F), and the B6 CTL clone 2C10 (G) were obtained by limit-
ing dilution and tested against RMA-S, RMA, and RMA-S loaded with GP33.
Figure 4. Recognition of self-MHC at
high ligand density by the CTL clone 27/30
is largely independent of peptide. (A) The
b2m2/2 CTL clone 27/30 was tested in a
51Cr-release CTL assay against RMA-S tar-
get cells loaded with LCMV GP33 peptide,
influenza NP366 peptide, Yop249 peptide,
unloaded RMA-S, or RMA-S incubated
for 12 h at 268C without peptide to stabilize
“empty” MHC class I on the cell surface.
(B) Clone 27/30 was tested against T2Db
target cells loaded with GP33, NP366,
Yop249, and unloaded T2Db. The T2 cell
line was included as a Db negative control.888 Functional Recognition of MHC Modulates T Cell Specificity
erly conformed H-2Db molecules (B22-249.1), the binding
of which is not affected by GP33 (data not shown). RMA
target cells were killed at similar levels regardless of the
presence or absence of specific peptide (Fig. 5). However,
in the absence of GP33 peptide the CTL killing activity
was efficiently blocked by 5.0 mg/ml of B22-249.1, whereas
virtually no blocking was observed when the RMA target
cells were prepulsed with the GP33 peptide at 378C (Fig.
5 A). FACS® analysis of B22-249.1 binding to RMA cells
did not allow accurate quantitation of the fraction of free
H-2Db ligands at half-maximal lysis, since half-maximal
blocking of CTL lysis was achieved at a concentration at
which staining was close to maximal (Fig. 5 B). However,
these experiments clearly demonstrate that triggering of
b2m2/2 CTLs in the absence of GP33 peptide requires a
considerably higher number of H-2Db ligands.
We next made a similar series of experiments using
T2Db cells as targets. These cells express the B22-249.1
epitope at levels ,10% those of RMA (Table II) but are
still killed by the b2m2/2 GP33-specific CTL clone 27/30
in the absence of specific peptide (Fig. 4 B). Lysis of T2Db
cells was blocked already at a 1.0 mg/ml concentration of
B22-249.1 in the CTL assay (Fig. 5 C), indicating that a
large fraction of cell surface H-2Db molecules is required
for triggering of this CTL clone. Pulsing of T2Db cells with
Figure 5. CTL triggering by self-MHC is a low-avidity event that requires interaction with a high density of ligands. (A) Recognition by b2m2/2
LCMV GP33-specific polyclonal CTLs of RMA in the absence or presence of GP33 peptide was blocked using the anti–H-2Db conformation-specific
mAb B22-249.1. (B) FACS® analysis of B22-249.1 titration on RMA cells. (C) Recognition by the GP33-specific b2m2/2 CTL clone 27/30 of T2Db
loaded with GP33, Yop249, NP366, or T2Db without peptide was blocked using B22-249.1. (D) FACS® analysis of B22-249.1 titration on T2Db. The
preincubation of target cells with peptide at 378C did not affect expression of H-2Db in these experiments (data not shown).
GP33 peptide prohibited blocking at all mAb concentra-
tions tested (Fig. 5 C). This effect was peptide specific,
since neither NP366 nor Yop249 had any effect on avidity
as determined by blocking with mAb. By titration of B22-
249.1 in FACS® analysis of T2Db (Fig. 5 D), the fraction of
free H-2Db ligands on T2Db at half-maximal peptide-inde-
pendent lysis was estimated at z80% (comparing Fig. 5, C
and D). Thus, z80% of the H-2Db molecules on T2Db
were necessary for peptide-independent recognition by the
high-avidity CTL clone 27/30, which corresponds to
about four times the level of folded H-2Db on b2m2/2 cells
(Table II). Taken together, these data indicate that b2m2/2
CTLs use peptide-independent recognition of a high num-
ber of H-2Db ligands to compensate for the absence of spe-
cific peptide.
GP33-specific b2m2/2 CTLs Are Less Dependent on the Ex-
act GP33 Peptide Sequence. Finally, we analyzed the con-
sequences of self-MHC avidity in GP33-specific B6 and
b2m2/2 CTLs in terms of peptide specificity, when MHC
was expressed at lower levels. Neither B6 nor b2m2/2
CTLs kill RMA-S (MHClow) in the absence of specific
peptide, and RMA-S cells require a pulse of z100 pM
GP33 peptide to become sensitive targets to both B6 and
b2m2/2 CTLs (Fig. 6). This shows that B6 and b2m2/2
CTLs require roughly equal amounts of H-2Db/GP33889 Sandberg et al.
complexes to get a triggering signal. However, when using
GP33 peptide variants alanine-substituted at one or several
TCR contact residues (reference 40, and data not shown),
the b2m2/2 CTLs recognized RMA-S cells pulsed with up
to 1,000-fold less peptide than B6 CTLs (Fig. 6). Substitu-
tion at one position (GP33-4A) already drastically reduced
the efficiency of B6 CTLs against peptide-pulsed RMA-S
targets, whereas b2m2/2 CTLs could still recognize pep-
tides with alanine substituted at two positions. Thus, al-
though b2m2/2 CTLs were still peptide specific, they were
less dependent on the TCR contact residues in the peptide
when the peptide was loaded on RMA-S target cells
(which express about three times the levels of H-2Db found
on b2m2/2 cells [Table II]). These data indicate that the
avidities for peptide and MHC both contribute function-
ally to the triggering of CTLs, and that they can be consid-
ered separately. Further, increased avidity for the restriction
element compensates for a reduced avidity for the peptide.
Discussion
Contribution of Peptide-independent Recognition of MHC to
the Specificity of T Cells. In this paper we have investigated
the influence of TCR interaction with self-MHC in recog-
nition of MHC-bound peptides. To address this issue, we
used MHC class I–restricted CD81 T cells selected and
primed in an environment with high (B6) or low (b2m2/2)
MHC expression (25). We find that self-MHC can deliver
a triggering signal independently of specific peptide, pro-
vided there is an increase in self-MHC density. The low
surface density of H-2 expressed on RMA-S cells was not
sufficient to trigger either b2m2/2 or B6 CTLs in the ab-
sence of the specific antigen, but increasing the ligand density
by cold temperature incubation could sensitize RMA-S to
the b2m2/2 CTL clone 27/30. Furthermore, since T2Db
cells were also killed irrespective of loaded peptide, recog-
nition of syngeneic class I was most probably peptide inde-
pendent. These results indicate that the interaction between
TCR and self-MHC as observed in crystals not only pro-
vides the structural framework of specific T cell recogni-
tion, it also contributes a part of the avidity required for
CTL triggering.
Table II. Surface Expression of H-2Db on Cells with Defects in 
TAP or b2m
Cell type
H-2Db expression
(mean FL1)*
H-2Db surface density
(FL1/FSC)‡
B6§ 227 398
TAP12/2 14 24
b2m2/2 46
TAP1/b2m2/2 00
RMA 396 568
RMA-S 15 21
T2Db 28 31
T2 0 0
*H-2Db expression was measured by FACS® analysis using the confor-
mation-dependent B22-249.1 epitope.
‡As forward scatter (FSC) is proportional to the cross-sectional area of
the analyzed cell, FL1/FSC was used as an estimate of the surface den-
sity of H-2Db.
§B6, TAP12/2,  b2m2/2, and TAP1/b2m2/2 Con A–activated blasts
were generated by culturing splenocytes for 3 d in RPMI supple-
mented with 10% FCS and 5 mg/ml Con A.
Figure 6. b2m2/2 CTLs display increased peptide promiscuity in rec-
ognition of MHC–peptide ligands. Groups of three B6 and three b2m2/2
mice were immunized with LCMV GP33 peptide as described in Materi-
als and Methods. After 12 d, immune splenocytes were restimulated with
GP33 for 6 d and tested in a 51Cr-release assay against RMA-S target cells
loaded with titrated amounts of GP33 and GP33 variants: GP33
KAVYNFATM; GP33-4A KAVANFATM; GP33-34A KAAANFATM;
and GP33-348A KAAANFAAM.890 Functional Recognition of MHC Modulates T Cell Specificity
Recognition of MHChigh targets by b2m2/2 CTLs was
blocked by mAb against properly conformed Db molecules,
whereas the presence of specific peptide prohibited blocking.
These results indicated that the lack of GP33 was compensated
by using an increased number of low-avidity interactions with
self-MHC. The results further suggest that a minimum of four
times the level of MHC class I expression present during selec-
tion and priming in vivo were necessary for activation by self-
MHC to occur in vitro. RMA-S expresses only about three
times the level of MHC found on b2m2/2 cells (Table II),
which may explain why b2m2/2 CTLs were peptide specific
when tested against RMA-S targets. In the presence of specific
GP33 peptide, no mAb-mediated blocking of MHChigh target
cell killing was observed. This supports the notion that MHC-
restricted CTLs have a high avidity for the peptide antigen and
a low avidity for self-MHC.
Interestingly, we found that T cells with an increased
avidity for MHC class I molecules had a more relaxed pep-
tide specificity, i.e., they were less dependent on the exact
peptide sequence. While both B6 and b2m2/2 GP33-spe-
cific CTLs had similar sensitivity for GP33, b2m2/2 CTLs
had superior sensitivity for peptides lacking one or several
TCR contact residues of the GP33 peptide. Thus, in-
creased recognition of the restriction element compensates
for lack of TCR peptide affinity in recognition of low-
affinity peptide ligands.
Our data argue that recognition of the two entities of the
MHC complex, peptide and MHC heavy chain, can be
considered separately (41). Increased recognition of MHC
could substitute for lack of peptide recognition. The indi-
cation that TCR avidity for its ligand can be subdivided in
this way opens the possibility of extending the differential
avidity model of T cell selection and recognition (42).
Implications for the Avidity Threshold in T Cell Recognition.
The present data can be interpreted within a model for T
cell recognition based on the total avidity contributed by
TCR affinity for MHC, affinity for peptide, and the num-
ber of MHC–peptide complexes. Increased avidity for
MHC can compensate for lack of avidity for peptide, sug-
gesting that these binding forces are functionally inter-
changeable and can be considered separately (Fig. 7 A).
This would suggest a variation in the avidities for MHC
and presented antigens among mature CTLs (See also Fig.
3, D–G). Interestingly, mice deficient in terminal deoxy-
nucleotidyl transferase (TdT), which lack N-region addi-
tions in the TCR, display increased promiscuity in T cell
recognition of peptide ligands (43). In this situation, MHC
was suggested to provide compensatory avidity in recogni-
tion of peptide antigen by TdT2/2 CTLs. Further, the data
in this paper support an inverse correlation between the
number of MHC–peptide ligands necessary for triggering
and TCR avidity for the ligand (for data, see Fig. 5; for
model, see Fig. 7 B). Lower avidity for an antigen would
then be compensated by an increase in antigen density.
This feature becomes most important for CTLs with a rela-
tively high MHC avidity, since self-MHC can be regarded
as a high-density and low-affinity ligand.
By combining Fig. 7, A and B, a hypothetical three-
dimensional diagram can be generated in which the surface
depicts how the TCR affinities for peptide and MHC, and
the number of ligands necessary for triggering, are inter-
changeable (Fig. 7 C). The diagram proposes that when the
TCR avidities for both peptide and MHC are low, the
number of ligands necessary to achieve triggering will be
high. We would like to suggest further that the same model
would apply for thymic selection, where the threshold co-
ordinates for positive selection would be considerably
lower on all axes while coordinates for negative selection
would be closer to the threshold for triggering of effector
functions.
Figure 7. The TCR avidity threshold for T cell recognition. Hypothetical diagrams illustrating how the TCR affinities for peptide and MHC are in-
terchangeable and mutually compensatory (A), and how the number of MHC–peptide ligands necessary for triggering inversely correlates with the TCR
affinity for the ligand (B). (C) A and B are combined to generate a threshold composed of TCR affinities for MHC and peptide and the number of
MHC–peptide complexes. In this threshold, all three contributing components can compensate for each other to generate the avidity necessary for T cell
activation. The curve in A is presented as a straight line because a constant combined value of MHC–peptide avidity required for CTL triggering is sub-
divided into two parts, representing avidity for either MHC (x-axis) or peptide (y-axis). The shape of the curve in B is hypothetical. However, the hy-
perbolic shape will result if the total avidity required for triggering is constant, and if this avidity is a product of the number of ligands and the TCR af-
finity for each of these ligands (i.e., total triggering avidity 5 no. of ligands 3 TCR affinity for each ligand).891 Sandberg et al.
Aspects of CD81 T Cell Selection in the Absence of b2m.
Selection of H-2Db–restricted T cells specific for the GP33
epitope in b2m2/2 mice is thymus dependent, and results
in a peripheral repertoire biased towards recognition of the
restriction element expressed with and without self-pep-
tides. However, peptide-independent triggering occurs
only when MHC is expressed at levels considerably higher
than those encountered by the T cells in vivo. This indi-
cates repertoire calibration during thymic selection to fit
the self-MHC ligand density in the periphery. Our results
fit very well with the notion that T cells being selected in
the thymus view self-MHC as a low-affinity ligand. Self-
ligands capable of triggering induce deletion, and in the pe-
riphery self-MHC never reaches the ligand density to trig-
ger CTLs in the absence of triggering antigens. It should be
noted that in addition to the increased recognition of
MHC, the b2m2/2 CTLs may also display an increased
avidity for self-peptides. There may be a clonal variation in
recognition of MHC and peptide within the b2m2/2 CTL
population, where the clone 27/30 represents the most
peptide-independent phenotype.
Considering the low expression of MHC present during
selection in the b2m2/2 mice, it is possible that the CD81
T cells use upregulation of (co)receptor expression to
achieve positive selection. Indeed, we have observed a
marginal increase in CD8 expression in some of the b2m2/2
CTLs, which potentially could also contribute to the ele-
vated recognition of self-MHC. However, in functional
experiments based on recognition of GP33 and alanine-
substituted variants, we have observed that b2m2/2 CTLs
are less susceptible to CD8 blocking with anti-CD8a mAbs
compared with B6 CTLs. This result would suggest, rather,
a decreased dependency on CD8 in triggering of b2m2/2
CTLs (data not shown).
Accumulating evidence suggests that the CD81 T cells
present in the b2m2/2 mice have retained important char-
acteristics of the b2m1/1 wild-type concerning development
and recognition of MHC. First, b2m2/2 mice can generate
in vivo CTL responses against MHC class I–restricted pep-
tide (44; and this study) and viral (45) antigens, and reject
skin grafts over a minor histocompatibility barrier (46).
Also, b2m2/2 CTLs can recognize peptide antigens on
b2m1/1 targets (this study). Second, development of b2m2/2
CD81 T cells is dependent on the thymus (this study), and
results in a CD81 T cell repertoire biased towards recogni-
tion of syngeneic class I (23; and this study). Third, H-2Db
heavy chains expressed in the absence of b2m are recog-
nized by conformation-dependent mAbs (27, 28, 47; and
this study), and expression is TAP dependent (32; and this
study). Note also that all detectable b2m2/2 CTL reactivity
against self-MHC could be blocked by an mAb specific for
properly conformed H-2Db molecules, which reduces the
likelihood for a role of aberrantly conformed free Db heavy
chains in this system. Fourth, wild-type CTLs can recog-
nize endogenously processed antigens (48) and alloantigens
(27, 48) on b2m2/2 cells. Taken together, these data sug-
gest that T cell selection follows the normal rules in b2m2/2
mice, although the selection window is dramatically shifted
towards low ligand density. The confrontation of such T
cells with cells expressing normal MHC levels allows de-
tection of the T cell avidity for self-MHC. However, the
functional avidity must be established already during selec-
tion and must exist during priming. Thus, we propose that
T cells in normal mice have a similar avidity for self-MHC
which would be detectable by exposing them to cells with
supraoptimal MHC levels.
We have demonstrated that avidity for self-MHC can
trigger MHC-restricted T cells independently of specific
peptide if ligand density of self-MHC is sufficiently in-
creased. This interaction compensates for lack of TCR af-
finity for peptide, and it depends on a TCR–MHC interac-
tion of relatively low affinity that requires high numbers of
MHC ligands. The data and the avidity threshold model
discussed contribute to our understanding of T cell speci-
ficity in the periphery and during thymic selection.
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